-
1
-
-
84862777419
-
Efficacy and safety of rilpi- virine (TMC278) versus efavirenz at 48 weeks in treatment-naïve, HIV- 1-infected patients: Pooled results from the phase 3 double-blind randomized ECHO and THRIVE trials
-
ECHO Study Group; THRIVE Study Group
-
Cohen, Molina JM, Cahn P, Clotet B, Fourie J, Grinsztejn B, et al.; ECHO Study Group; THRIVE Study Group. Efficacy and safety of rilpi- virine (TMC278) versus efavirenz at 48 weeks in treatment-naïve, HIV- 1-infected patients: pooled results from the phase 3 double-blind randomized ECHO and THRIVE trials. J Acquir Immune Defic Syndr. 2012;60:33-42.
-
(2012)
J Acquir Immune Defic Syndr
, vol.60
, pp. 33-42
-
-
Cohen1
Molina, J.M.2
Cahn, P.3
Clotet, B.4
Fourie, J.5
Grinsztejn, B.6
-
2
-
-
75749118495
-
TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1
-
Azijn H, Tirry I, Vingerhoets J, de Béthune MP, Kraus G, Boven K, et al. TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1. Antimicrob Agents Chemother. 2010; 54 : 718-27.
-
(2010)
Antimicrob Agents Chemother
, vol.54
, pp. 718-727
-
-
Azijn, H.1
Tirry, I.2
Vingerhoets, J.3
De Béthune, M.P.4
Kraus, G.5
Boven, K.6
-
3
-
-
79960381844
-
ECHO study group. Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naïve adults infected with HIV-1 (ECHO): A phase 3 randomised double-blind active-controlled trial
-
Molina JM, Cahn P, Grinsztejn B, Lazzarin A, Mills A, Saag M, et al.; ECHO study group. Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naïve adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial. Lancet. 2011;378:238-46.
-
(2011)
Lancet
, vol.378
, pp. 238-246
-
-
Molina, J.M.1
Cahn, P.2
Grinsztejn, B.3
Lazzarin, A.4
Mills, A.5
Saag, M.6
-
4
-
-
79960358849
-
THRIVE study group. Rilpivirine versus efa- virenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naïve adults infected with HIV-1 (THRIVE): A phase 3, randomized, non-inferiority trial
-
Cohen CJ, Andrade-Villanueva J, Clotet B, Fourie J, Johnson MA, Ruxrungtham K, et al.; THRIVE study group. Rilpivirine versus efa- virenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naïve adults infected with HIV-1 (THRIVE): a phase 3, randomized, non-inferiority trial. Lancet. 2011;378:229-37.
-
(2011)
Lancet
, vol.378
, pp. 229-237
-
-
Cohen, C.J.1
Andrade-Villanueva, J.2
Clotet, B.3
Fourie, J.4
Johnson, M.A.5
Ruxrungtham, K.6
-
5
-
-
84871651718
-
Pooled week 96 efficiency, resistance and safety results from the double-blind, randomised, phase III trials comparing rilpivirine (RPV) versus efavirenz (EFV) in treatment-naive, HIV-1 infected adults
-
Rome, Italy, 17-20 July 2011, Abstract no. TULBPE032
-
Cohen CJ, Molina JM, Cassetti I, Chetchotisakd P, Lazzarin A, Rhame F, et al. Pooled week 96 efficiency, resistance and safety results from the double-blind, randomised, phase III trials comparing rilpivirine (RPV) versus efavirenz (EFV) in treatment-naive, HIV-1 infected adults. Conference on HIV Pathogenesis, Treatment and Prevention, Rome, Italy, 17-20 July 2011, Abstract no. TULBPE032.
-
Conference on HIV Pathogenesis, Treatment and Prevention
-
-
Cohen, C.J.1
Molina, J.M.2
Cassetti, I.3
Chetchotisakd, P.4
Lazzarin, A.5
Rhame, F.6
-
6
-
-
84863190048
-
Effect of gender and race on the week 48 findings in treatment- naïve, HIV-1- infected patients enrolled in the randomized, phase III trials ECHO and THRIVE
-
Hodder S, Arasteh K, De Wet J, Gathe J, Gold J, Kumar P, et al. Effect of gender and race on the week 48 findings in treatment-naïve, HIV-1- infected patients enrolled in the randomized, phase III trials ECHO and THRIVE. HIV Med. 2012;13:406-15.
-
(2012)
HIV Med
, vol.13
, pp. 406-415
-
-
Hodder, S.1
Arasteh, K.2
De Wet, J.3
Gathe, J.4
Gold, J.5
Kumar, P.6
-
7
-
-
84873933904
-
Switching from efavirenz-emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) single table regimen (STR) to emtricitabine/rilpivirine/tenofovir disoproxil fumarate (FTC/RPV/TDF) STR in virologically suppressed, HIV-1 infected subjects
-
Chicago, IL, 17-20 September 2011. Poster H2-794c
-
Mills A, Cohen C, Dejesus E, Rashbaum B, Brinson C, Yale K, et al. Switching from efavirenz-emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) single table regimen (STR) to emtricitabine/rilpivirine/tenofovir disoproxil fumarate (FTC/RPV/TDF) STR in virologically suppressed, HIV-1 infected subjects. Presented at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Chicago, IL, 17-20 September 2011. Poster H2-794c.
-
51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)
-
-
Mills, A.1
Cohen, C.2
Dejesus, E.3
Rashbaum, B.4
Brinson, C.5
Yale, K.6
-
8
-
-
84939288210
-
Pharmacokinetic parameters of once-daily TMC278 following administration of efavirenz in healthy volunteers
-
Boston, MA, 27 February-2 March 2011. Poster N143
-
Crauwels H, Vingerhoets J, Ryan R, Witek J, Anderson D. Pharmacokinetic parameters of once-daily TMC278 following administration of efavirenz in healthy volunteers. Presented at the 18th Conference on Retroviruses and Opportunistic Infections (CROI), Boston, MA, 27 February-2 March 2011. Poster N143.
-
18th Conference on Retroviruses and Opportunistic Infections (CROI)
-
-
Crauwels, H.1
Vingerhoets, J.2
Ryan, R.3
Witek, J.4
Anderson, D.5
-
9
-
-
84864505008
-
Efficacy and safety of rilpivirine in treatment-naive, HIV- 1-infected patients with hepatitis B virus/hepatitis C virus coinfection enrolled in the Phase III randomized, double-blind ECHO and THRIVE trials
-
Nelson M, Amaya G, Clumeck N, Arns da Cunha C, Jayaweera D, Junod P, et al. Efficacy and safety of rilpivirine in treatment-naive, HIV- 1-infected patients with hepatitis B virus/hepatitis C virus coinfection enrolled in the Phase III randomized, double-blind ECHO and THRIVE trials. J Antimicrob Chemother. 2012;67:2020-8.
-
(2012)
J Antimicrob Chemother
, vol.67
, pp. 2020-2028
-
-
Nelson, M.1
Amaya, G.2
Clumeck, N.3
Arns Da Cunha, C.4
Jayaweera, D.5
Junod, P.6
-
10
-
-
73649148381
-
TMC278-C204 Study Group. Efficacy and safety of TMC278 in antiretroviral-naïve HIV-1 patients: Week 96 results of a phase IIb randomized trial
-
Pozniak AL, Morales-Ramirez J, Katabira E, Steyn D, Lupo SH, Santos- coy M, et al.; TMC278-C204 Study Group. Efficacy and safety of TMC278 in antiretroviral-naïve HIV-1 patients: week 96 results of a phase IIb randomized trial. AIDS. 2010;24:55-65.
-
(2010)
AIDS
, vol.24
, pp. 55-65
-
-
Pozniak, A.L.1
Morales-Ramirez, J.2
Katabira, E.3
Steyn, D.4
Lupo, S.H.5
Santoscoy, M.6
-
11
-
-
84860455337
-
Longterm efficacy, safety, and tolerability of rilpivirine (RPV, TMC278) in HIV type 1-infected antiretroviral-naive patients: Week 192 results from a phase IIb randomized trial
-
on behalf of the TMC278-C204 Study Group
-
Wilkin A, Pozniak AL, Morales-Ramirez J, Lupo SH, Santoscoy M, Grinsztejn B, et al.; on behalf of the TMC278-C204 Study Group. Longterm efficacy, safety, and tolerability of rilpivirine (RPV, TMC278) in HIV type 1-infected antiretroviral-naive patients: week 192 results from a phase IIb randomized trial. AIDS Res Hum Retroviruses. 2012 ï 28 : 437-46.
-
(2012)
AIDS Res Hum Retroviruses
, vol.28
, pp. 437-446
-
-
Wilkin, A.1
Pozniak, A.L.2
Morales-Ramirez, J.3
Lupo, S.H.4
Santoscoy, M.5
Grinsztejn, B.6
-
12
-
-
40349091258
-
High-resolution structures of HIV-1 reverse transcriptase/TMC278 complexes: Strategic flexibility explains potency against resistance mutations
-
DOI 10.1073/pnas.0711209105
-
Das K, Bauman JK, Clark AD Jr, Frenkel YV, Lewi PJ, Shatkin AJ, et al. High-resolution structures of HIV-1 reverse transcriptase/TMC278 complexes: strategic flexibility explains potency against resistance mutations. Proc Nat Acad Sci USA. 2008;105:1466-71. (Pubitemid 351346537)
-
(2008)
Proceedings of the National Academy of Sciences of the United States of America
, vol.105
, Issue.5
, pp. 1466-1471
-
-
Das, K.1
Bauman, J.D.2
Clark Jr., A.D.3
Frenkel, Y.V.4
Lewi, P.J.5
Shatkin, A.J.6
Hughes, S.H.7
Arnold, E.8
-
13
-
-
83655163698
-
Genotypic and phenotypic characterization of HIV-1 isolates obtained from patients on rilpivirine therapy experiencing virologic failure in the Phase 3 ECHO and THRIVE studies: 48-week analysis
-
Rimsky L, Vingerhoets J, Van Eygen V, et al. Genotypic and phenotypic characterization of HIV-1 isolates obtained from patients on rilpivirine therapy experiencing virologic failure in the Phase 3 ECHO and THRIVE studies: 48-week analysis. J Acquir Immune Defic Syndr. 2012;59:39-46.
-
(2012)
J Acquir Immune Defic Syndr
, vol.59
, pp. 39-46
-
-
Rimsky, L.1
Vingerhoets, J.2
Van Eygen, V.3
-
14
-
-
78751693611
-
Characterization of the E138K resistance mutation in HIV-1 reverse transcriptase on susceptibility to etravirine in B and non-B HIV-1 subtypes
-
Asahchop EL, Oliveira M, Wainberg MA, Brenner BG, Moisi D, Toni T, et al. Characterization of the E138K resistance mutation in HIV-1 reverse transcriptase on susceptibility to etravirine in B and non-B HIV-1 subtypes. Antimicrob Agents Chemother. 2011;55:600-7.
-
(2011)
Antimicrob Agents Chemother
, vol.55
, pp. 600-607
-
-
Asahchop, E.L.1
Oliveira, M.2
Wainberg, M.A.3
Brenner, B.G.4
Moisi, D.5
Toni, T.6
-
15
-
-
0036822850
-
Might the M184V substitution in HIV-1 RT confer clinical benefit?
-
Petrella M, Wainberg MA. Might the M184V substitution in HIV-1 RT confer clinical benefit? AIDS Rev. 2002;4:224-32. (Pubitemid 36104233)
-
(2002)
AIDS Reviews
, vol.4
, Issue.4
, pp. 224-232
-
-
Petrella, M.1
Wainberg, M.A.2
-
16
-
-
80055119045
-
Compensation by the E138K mutation in HIV-1 reverse transcriptase for deficits in viral replication capacity and enzyme proces- sivity associated with the M184I/V mutations
-
Xu HT, Asahchop EL, Oliveira M, Quashie PK, Quan Y, Brenner BG, et al. Compensation by the E138K mutation in HIV-1 reverse transcriptase for deficits in viral replication capacity and enzyme proces- sivity associated with the M184I/V mutations. J Virol. 2011;85: 11300-8.
-
(2011)
J Virol
, vol.85
, pp. 11300-11308
-
-
Xu, H.T.1
Asahchop, E.L.2
Oliveira, M.3
Quashie, P.K.4
Quan, Y.5
Brenner, B.G.6
-
17
-
-
80055103177
-
Interaction of reverse transcriptase (RT) mutations conferring resistance to lamivudine and etravirine: Effects on fitness and RT activity of human immunodeficiency virus type 1
-
Hu Z, Kuritzkes DR. Interaction of reverse transcriptase (RT) mutations conferring resistance to lamivudine and etravirine: effects on fitness and RT activity of human immunodeficiency virus type 1. J Virol. 2011;85:11309-14.
-
(2011)
J Virol
, vol.85
, pp. 11309-11314
-
-
Hu, Z.1
Kuritzkes, D.R.2
-
18
-
-
83655201316
-
Thie HIV-1 reverse transcriptase M184I mutation enhances the E138K-associated resistance to rilpivirine and decreases viral fitness
-
Kulkarni R, Babaoglu K, Lansdon EB, Rimsky L, Van Eygen V, Picchio G, et al. Thie HIV-1 reverse transcriptase M184I mutation enhances the E138K-associated resistance to rilpivirine and decreases viral fitness. J Acquir Immune Defic Syndr. 2012;59:47-54.
-
(2012)
J Acquir Immune Defic Syndr
, vol.59
, pp. 47-54
-
-
Kulkarni, R.1
Babaoglu, K.2
Lansdon, E.B.3
Rimsky, L.4
Van Eygen, V.5
Picchio, G.6
-
20
-
-
84876110905
-
-
(accessed 22 August 2012)
-
Janssen, Edurant™ European Medicines Agency product information. Available at: http://www.ema.europa.eu/docs/en-GB/document-library/ EPAR-Product-Information/human/002264/WC500118874.pdf (accessed 22 August 2012).
-
Janssen, Edurant™ European Medicines Agency Product Information
-
-
|